1 Day
المصدر:
Financial Times
AstraZeneca investors express merger worries
Shareholders are raising concerns about a potential $400 billion merger between an undisclosed company and Bristol Myers Squibb, citing risks related to upcoming patent expirations and antitrust issues.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading